This ADC product is composed of an anti-Her2 antibody conjugated via vc linker to [14C]MMAE (trastuzumab-vc-[14C]MMAE). It has demonstrated a response in HER2-positive breast cancer treatment by a MOA (Mechanism of Action) of microtubules depolymerizing.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-059 | Recombinant Anti-Human ERBB2 VHH Single Domain Antibody | IHC, FC, CA, FuncS | Llama VHH |
PNBL-066 | Recombinant Anti-HER2 VHH Single Domain Antibody (PNBL-066) | SPR | Llama VHH |
HPAB-0201-FY | Recombinant llama Anti-ERBB2 Antibody (HPAB-0201-FY) | E | llama VHH |
HPAB-0202-FY | Recombinant llama Anti-ERBB2 Antibody (HPAB-0202-FY) | E | llama VHH |
HPAB-0203-FY | Recombinant llama Anti-ERBB2 Antibody | IF | llama VHH |
There are currently no Customer reviews or questions for ADC-221LZY. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.